Pulsed Electric Field Ablation Plus SBRT Preserves Quality of Life in Lung Tumors
Key Clinical Summary
- Prospective pilot study included 6 patients with 8 lung tumors, targeting oligometastatic or oligoprogressive disease.
- Combination pulsed electric field (PEF) ablation and low-dose SBRT showed no significant decline in quality of life or pulmonary function at 3 months.
- Findings support feasibility of tissue-sparing local therapy, but require validation and comparison against conventional treatments in larger trials.
Introduction
A novel combination of pulsed electric field (PEF) ablation and stereotactic body radiation therapy (SBRT) may offer a safe local treatment option for lung tumors without compromising patient quality of life. In a prospective pilot study published in Lung Cancer Management on March 5, 2026, investigators evaluated the impact of this combined modality on health-related quality of life (HRQoL) and pulmonary function in patients with oligometastatic or oligoprogressive disease.1
Study Findings
The single-arm prospective trial enrolled 6 patients with a total of 8 lung tumors. Participants underwent PEF ablation followed by single-fraction, lower-dose SBRT (12 Gy), with HRQoL assessed using validated FACT-Lung Cancer Subscale (FACT-LCS) and FACT-General instruments at baseline, 3 months, and 12 months.
At 3 months, investigators observed no statistically significant changes in any HRQoL domain, nor in pulmonary function metrics—including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO).
The study also identified associations between lower emotional and social well-being scores and poorer pulmonary function, suggesting an interaction between psychosocial and physiologic health status.
Authors emphasized that “no clinically meaningful declines” were observed in either HRQoL or pulmonary function at early follow-up, supporting the tolerability of the combined approach.
Clinical Implications
Management of oligometastatic and oligoprogressive lung tumors is evolving, with increasing utilization of local therapies. However, treatment of central or ultracentral lung lesions remains challenging due to the risk of toxicity with conventional SBRT.
The addition of PEF ablation introduces a nonthermal, tissue-sparing modality that produces smaller ablation zones, potentially reducing collateral damage to surrounding structures; when combined with lower-dose SBRT, this approach represents a tissue-sparing local therapy strategy that reduces toxin exposure.
Quality of life is a critical endpoint in metastatic settings, where therapeutic decisions often balance survival benefit against treatment burden. The absence of HRQoL deterioration in this study suggests that combination PEF-SBRT may align with patient-centered care goals.
Expert Perspectives
Importantly, the authors noted that “the rapid disease progression observed in all patients (median 4.6 months to off-target progression) suggests that any observed HRQoL stability at 12 months in evaluable patients is likely attributable to lack of treatment-related toxicity rather than favorable disease control.”
They also caution against generalizability due to the small sample size, patient heterogeneity, and single-arm design. Ultimately, the findings are hypothesis-generating and underscore the need for larger, controlled trials to evaluate efficacy, durability of response, and comparative effectiveness vs standard therapies.
Conclusions
This pilot study demonstrates that combining PEF ablation with low-dose SBRT preserves quality of life and pulmonary function in patients with lung tumors in the short-term. While promising, further research is needed to validate these findings and define the role of this novel approach in clinical practice.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.
